Jyseleca failure in Crohn's will shift pipeline attention to novel target

3 March 2023
galapagos_large

Belgian biotech Galapagos’ (Euronext: GLPG) suffered a disappoint earlier this month, when its already commercialized JAK inhibitor Jyseleca (filgotinib) fell short in the induction cohorts of a Phase III Crohn's disease (CD) trial.

Responding to the development, analytics firm GlobalData noted that the results are expected to shift the attention of the late-stage CD pipeline from established drug classes such as the Janus kinase or the interleukin-23 (IL-23) inhibitors towards developing novel CD therapeutic targets.

Among the 19 assets in late-stage clinical development, only six (ozanimod, etrasimod, obefazimod, TEV-48574, PRA-023, PF-0648065) are being pursued as first-in-class for novel therapeutic targets in CD.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars